Ethylenediamine-N,N'-di(acetic acid)

Endpoint summary

Description of key information

It is considered highly likely that ED2A will behave similarly to (H)EDTA and on this basis it is expected to poorly absorb across the gastrointestinal tract and will be excreted  rapidly and largely unchanged. Dermal absorption is expected to be minimal.

Key value for chemical safety assessment

Bioaccumulation potential:

low bioaccumulation potential

Absorption rate - oral (%):

10

Absorption rate - dermal (%):

0.1

Additional information

There were no studies available on the absorption, metabolism, distribution or elimination (AMDE) for ED2A, but there are for EDTA. Toxicokinetic studies on humans and on rats indicate that the structural analogue, EDTA, is poorly absorbed across the gastrointestinal tract. The absorbed EDTA did not undergo any biotransformation and was rapidly excreted unchanged in urine. However it was noted that there is an increase in excretion of necessary ions such as Zn, Mn or Ca. It is considered that ED2A will behave similarly to EDTA and on this basis it is expected to poorly absorb across the gastrointestinal tract and will be excreted rapidly and largely unchanged (see read across document).

In a study on young, healthy, male volunteers Foreman etal (1954) investigated the dermal absorption of CaNa2 -EDTA. 3 mg of a mixture of¹⁴C labelled and unlabeled substance was prepared in a water soluble base which was applied over an area of 100 cm² for 24 hours under occlusive conditions. The maximum activity in the urine was 0.001% of the administered dose. The same is expected for ED2A.